Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 16/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 1.00 |
| ▸ | UBA1 | P22314 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Largazole SCHEMBL7937167 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL2611944 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL31485751 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL91139 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL23760411 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL71330 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL10314988 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL14973971 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| Largazole SCHEMBL2611945 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6NCOR2 | |
| SCHEMBL13453167 | 0.97 | HDAC1 (0.94) | HDAC1HDAC3HDAC2HDAC6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | HDAC1 2244/4885HDAC3 2049/4885HDAC2 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.